Fanconi anemia (FA) homozygotes have an increased cancer predisposition. In addition to the extraordinarily high frequency of AML in FA patients (actuarial risk of 52 percent for the development of MDS and/or AML by 40 years of age), FA patients exhibit malignancies of a variety of organ systems, most commonly gastrointestinal and gynecologic. The high incidence of nonhematologic malignancy in FA patients is especially striking because of the predicted early death from hematologic causes associated with the syndrome. Thus patients are unusually young when they develop cancer, and the incidence of malignancy probably would be considerably higher if patients had a longer life expectancy. There is evidence that heterozygote carriers of homozygous recessive familial cancer syndromes, such as Fanconi anemia, ataxia telangiectasia and xeroderma pigmentosum, are at increased risk for cancer. It is now possible to ascertain the carrier status by means of molecular tests rather than impute carrier status through probabilities, and thus it may be possible to arrive at a definitive answer to the role of heterozygosity among Fanconi anemia carriers. This study will directly address the etiology of cancer that involves the role of Fanconi anemia heterozygosity. The major aim of this retrospective cohort study will be to evaluate whether FA heterozygotes are at increased risk for developing cancer. In order to address this aim this study will use the extensive resources of the International Fanconi Anemia Registry at Rockefeller University. The sample will consist of 758 Fanconi anemia heterozygote grandparents of FA probands and 758 grandparents who do not carry an FA allele. Risk factor information will be obtained by questionnaire, blood will be collected for DNA analysis, and diagnostic pathology information will be collected using a systematic approach. Analyses will be undertaken to evaluate the role of Fanconi anemia heterozygosity for cancer. If carriers are found to be at increased risk, this information can be used to target individuals for cancer prevention strategies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
3R01CA082678-04S2
Application #
7034442
Study Section
Epidemiology and Disease Control Subcommittee 2 (EDC)
Program Officer
Ogunbiyi, Peter
Project Start
2001-04-01
Project End
2005-12-31
Budget Start
2004-04-01
Budget End
2005-12-31
Support Year
4
Fiscal Year
2005
Total Cost
$77,510
Indirect Cost
Name
University of New Mexico
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
868853094
City
Albuquerque
State
NM
Country
United States
Zip Code
87131
Berwick, Marianne; Satagopan, Jaya M; Ben-Porat, Leah et al. (2007) Genetic heterogeneity among Fanconi anemia heterozygotes and risk of cancer. Cancer Res 67:9591-6
Reid, Sarah; Schindler, Detlev; Hanenberg, Helmut et al. (2007) Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet 39:162-4
Ling, Chen; Ishiai, Masamichi; Ali, Abdullah Mahmood et al. (2007) FAAP100 is essential for activation of the Fanconi anemia-associated DNA damage response pathway. EMBO J 26:2104-14
Kalb, Reinhard; Neveling, Kornelia; Hoehn, Holger et al. (2007) Hypomorphic mutations in the gene encoding a key Fanconi anemia protein, FANCD2, sustain a significant group of FA-D2 patients with severe phenotype. Am J Hum Genet 80:895-910
Chandra, Saurabh; Levran, Orna; Jurickova, Ingrid et al. (2005) A rapid method for retrovirus-mediated identification of complementation groups in Fanconi anemia patients. Mol Ther 12:976-84
Satagopan, J M; Ben-Porat, L; Berwick, M et al. (2004) A note on competing risks in survival data analysis. Br J Cancer 91:1229-35
Kutler, David I; Wreesmann, Volkert B; Goberdhan, Andy et al. (2003) Human papillomavirus DNA and p53 polymorphisms in squamous cell carcinomas from Fanconi anemia patients. J Natl Cancer Inst 95:1718-21
Kutler, David I; Singh, Bhuvanesh; Satagopan, Jaya et al. (2003) A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood 101:1249-56
Kutler, David I; Auerbach, Arleen D; Satagopan, Jaya et al. (2003) High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia. Arch Otolaryngol Head Neck Surg 129:106-12